Terapia Ranbaxy, a subsidiary of Ranbaxy Laboratories, has received market authorisations (MAs) for 20 new products."The list of MAs granted by the National Agency of Medicine, Romania refers to products from different therapeutic areas, mainly from the cardiovascular, antibiotics and CNS segments," Dragos Damian, CEO, Terapia Ranbaxy, said. "These are either new molecules on the market like Citaloran or unique and modern formulations or concentrationslike Lamotiran - oral dispersible tablets, Pravator, Quinaran, Terbinaran or Glimeran among others," he added.According to Damian, the new launches reinforce the company's promise to bring value-added niche products at affordable prices to the Romanian pharmaceutical market.
